SCP-1 cancer/testis antigen is a prognostic indicator and a candidate target for immunotherapy in epithelial ovarian cancer

Jonathan Tammela, Achim A. Jungbluth, Feng Qian, Darren Santiago, Matthew J. Scanlan, Bernadette Keitz, Deborah Driscoll, Kerry Rodabaugh, Shashikant Lele, Lloyd J. Old, Kunle Odunsi

Research output: Contribution to journalArticle

24 Scopus citations

Abstract

SCP-1 is a novel tumor antigen that belongs to the growing family of cancer/testis (CT) antigens, and it is a potential target for immunotherapy. In an effort to determine the expression of SCP-1 in epithelial ovarian cancer (EOC), one-step RT-PCR was performed with RNA from epithelial ovarian tumor tissues and with two normal ovarian surface epithelial cell lines. We used immunohistochemistry (IHC) to investigate SCP-1 expression in paraffin-fixed EOC samples and ELISA to test sera from a subgroup of patients for SCP-1 antibody. SCP-1 was expressed in 15 out of 100 (15%) primary tumors, as determined by RT-PCR. The normal ovarian surface epithelial cell lines were negative for SCP-1 expression, as were a panel of other normal tissues. None of the patients whose tumors were determined to be SCP-1 positive by RT-PCR expressed the antigen by IHC or demonstrated a humoral immune response by ELISA. Tumors that expressed SCP-1 mRNA tended to have a higher grade than those that did not (P = 0.03). There was a significant decrease in survival time (P = 0.004) for patients with SCP-1 mRNA-positive tumors compared to those with SCP-1 mRNA-negative tumors [median 25 mo, 95% confidence interval (CI) 0-56 mo; and median 97 mo, CI 32-162 mo, respectively]. The present study shows that SCP-1 mRNA expression in patients with EOC is associated with a poorer chance of survival. These findings imply that further evaluation of SCP-1 as a potential target for vaccine therapy in EOC is warranted.

Original languageEnglish (US)
JournalCancer Immunity
Volume4
StatePublished - Oct 18 2004

Keywords

  • Human
  • Immunohistochemistry
  • Ovarian cancer
  • Prognosis
  • RT-PCR
  • SCP-1

ASJC Scopus subject areas

  • Immunology
  • Cancer Research

Fingerprint Dive into the research topics of 'SCP-1 cancer/testis antigen is a prognostic indicator and a candidate target for immunotherapy in epithelial ovarian cancer'. Together they form a unique fingerprint.

  • Cite this

    Tammela, J., Jungbluth, A. A., Qian, F., Santiago, D., Scanlan, M. J., Keitz, B., Driscoll, D., Rodabaugh, K., Lele, S., Old, L. J., & Odunsi, K. (2004). SCP-1 cancer/testis antigen is a prognostic indicator and a candidate target for immunotherapy in epithelial ovarian cancer. Cancer Immunity, 4.